Table 1 Sensitivity and specificity of the PTPRGint1 locus CpG9 methylation in sporadic tumours and tumours associated with a specific MMR mutation
From: Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer
CpG9 | Sensitivity methylated tumours/total tumours | Specificity unmethylated normals/total normals a |
|---|---|---|
Sporadic adenomas | 100% (18/18) | 100% (10/10) |
Sporadic carcinomas | 94% (63/67) | 95.8% (46/48) |
MLH1 mutated | 100% (14/14) | 87% (20/23) |
MSH2 mutated | 96% (18/19) | 100% (24/24) |
MSH6 mutated | 86.7% (26/30) | 100% (14/14) |
Total Lynch | 92.1% (58/63) | 95.4% (62/65) |
